NEUROBO PHARMACEUTICALS INC (NRBO)

US64132R4048 - Common Stock

2.97  +0.05 (+1.71%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NRBO. NRBO was compared to 568 industry peers in the Biotechnology industry. While NRBO seems to be doing ok healthwise, there are quite some concerns on its profitability. NRBO is valued expensive and it does not seem to be growing.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NRBO has reported negative net income.
In the past year NRBO has reported a negative cash flow from operations.
In the past 5 years NRBO always reported negative net income.
NRBO had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -90.09%, NRBO is doing worse than 74.25% of the companies in the same industry.
NRBO's Return On Equity of -136.74% is on the low side compared to the rest of the industry. NRBO is outperformed by 62.52% of its industry peers.
Industry RankSector Rank
ROA -90.09%
ROE -136.74%
ROIC N/A
ROA(3y)-62.45%
ROA(5y)-121.04%
ROE(3y)-81.21%
ROE(5y)-165.85%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

NRBO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, NRBO has less shares outstanding
Compared to 5 years ago, NRBO has more shares outstanding
NRBO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -6.83, we must say that NRBO is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of NRBO (-6.83) is worse than 68.92% of its industry peers.
NRBO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.83
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 2.94 indicates that NRBO has no problem at all paying its short term obligations.
The Current ratio of NRBO (2.94) is worse than 66.07% of its industry peers.
A Quick Ratio of 2.94 indicates that NRBO has no problem at all paying its short term obligations.
The Quick ratio of NRBO (2.94) is worse than 64.48% of its industry peers.
Industry RankSector Rank
Current Ratio 2.94
Quick Ratio 2.94

More info and screens

1

3. Growth

3.1 Past

NRBO shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.77%.
EPS 1Y (TTM)-1.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1056.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 17.81% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-13.91%
EPS Next 2Y24.78%
EPS Next 3Y17.81%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NRBO. In the last year negative earnings were reported.
Also next year NRBO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

NRBO's earnings are expected to grow with 17.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.78%
EPS Next 3Y17.81%

More info and screens

0

5. Dividend

5.1 Amount

NRBO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUROBO PHARMACEUTICALS INC

NASDAQ:NRBO (10/22/2024, 1:27:59 PM)

2.97

+0.05 (+1.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap25.22M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -90.09%
ROE -136.74%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.94
Quick Ratio 2.94
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-1.77%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-13.91%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y